Rallybio and Candid Therapeutics announce merger agreement Mar 2, 2026 08:01AM
Rallybio Corporation (RLYB) Tops Q3 EPS by 56c Nov 6, 2025 04:33PM
Rallybio receives $12.5M milestone payment from Recursion for REV102 Sep 3, 2025 08:02AM
Recursion (RXRX) acquires full rights to oral HPP treatment REV102 Jul 8, 2025 08:03AM
Rallybio sells REV102 program to Recursion for up to $25 million Jul 8, 2025 08:02AM


Jul 8, 2025 07:55AM Rallybio Corporation (RLYB) Halted, News Pending
Jun 12, 2025 08:09AM Rallybio Corporation (RLYB) Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
May 8, 2025 05:24PM Rallybio Corporation (RLYB) Tops Q1 EPS by 7c
Apr 23, 2025 04:25AM Citizens JMP Reiterates Market Perform Rating on Rallybio Corp. (RLYB)
Apr 11, 2025 04:22PM Evercore ISI Downgrades Rallybio Corp. (RLYB) to In Line
Apr 8, 2025 12:46PM Citizens JMP Downgrades Rallybio Corp. (RLYB) to Market Perform
Apr 8, 2025 08:00AM Rallybio Corporation (RLYB) to Discontinue Development of RLYB212 for Prevention of FNAIT
Mar 13, 2025 04:33PM Rallybio Corporation (RLYB) Tops Q4 EPS by 55c
Feb 11, 2025 08:02AM Rallybio Corporation (RLYB) Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
Dec 3, 2024 07:03AM H.C. Wainwright Reiterates Buy Rating on Rallybio Corp. (RLYB)
Nov 27, 2024 08:00AM Rallybio Corporation (RLYB) Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
Nov 7, 2024 08:08AM Rallybio Corporation (RLYB) Tops Q3 EPS by 9c
Oct 29, 2024 08:01AM Rallybio Corporation (RLYB) Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212
Oct 1, 2024 07:05AM H.C. Wainwright Reiterates Buy Rating on Rallybio Corp. (RLYB)
Sep 23, 2024 08:01AM Rallybio Corporation (RLYB) to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
Sep 3, 2024 06:52AM H.C. Wainwright Reiterates Buy Rating on Rallybio Corp. (RLYB)
Aug 29, 2024 08:00AM Rallybio Corporation (RLYB) Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results
Aug 12, 2024 06:55AM Rallybio Corp. (RLYB) PT Lowered to $6 at H.C. Wainwright
Aug 9, 2024 08:36AM Rallybio Corporation (RLYB) Misses Q2 EPS by 30c
Jun 17, 2024 02:04PM Jones Trading Reiterates Buy Rating on Rallybio Corp. (RLYB)